Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PETER GRAHAM ROSE

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1972530293
CMS profile
271117
Location
CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$11.17

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $11.17 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Ethicon US, LLC $11.17 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PETER GRAHAM ROSE

NPI 1972530293 · CMS profile ID 271117

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972530293?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PETER GRAHAM ROSE, NPI 1972530293, CMS profile ID 271117. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972530293?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PETER GRAHAM ROSE, NPI 1972530293, CMS profile ID 271117. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972530293?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PETER GRAHAM ROSE, NPI 1972530293, CMS profile ID 271117, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1972530293?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ethicon US, LLC $11.1707/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718917213 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $409.23 5
PY2020 $11.17 1
PY2021 $253.76 3
PY2022 $97.13 2
PY2023 $243.38 4
PY2024 $2,619.87 5
PY2025 $120.53 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,915.82 36
PY2024 Principal investigator $122,555.68 90
PY2023 Principal investigator $83,530.41 18
PY2022 Principal investigator $185,097.72 27
PY2021 Principal investigator $115,797.72 18
PY2020 Principal investigator $248,307.25 23
PY2019 Principal investigator $509,138.01 42

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $575.49 12/31/2019 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with a germline BRCA mutation and Stage III-IV Ovarian Cancer who are in Complete or Partial Response Following First Line Platinum Based Chemotherapy No dispute reported 06/30/2026 685004629
Principal investigator 1 Genentech, Inc. $3,955.00 12/19/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125819
Principal investigator 1 Clovis Oncology, Inc. $5,470.00 12/16/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689455003
Principal investigator 1 TESARO, Inc. $34,568.10 11/18/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689414185
Principal investigator 1 Clovis Oncology, Inc. $11,116.25 11/14/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689455001
Principal investigator 1 TESARO, Inc. $34,568.10 11/13/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689414137
Principal investigator 1 Genentech, Inc. $2,044.00 11/12/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125813
Principal investigator 1 Genentech, Inc. $2,544.00 10/21/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125809
Principal investigator 1 Clovis Oncology, Inc. $6,581.25 10/11/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689454999
Principal investigator 1 Genentech, Inc. $5,308.00 10/10/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125803
Principal investigator 1 Genentech, Inc. $4,449.00 10/04/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125799
Principal investigator 1 TESARO, Inc. $34,568.10 09/18/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689413109
Principal investigator 1 Seattle Genetics, Inc. $597.50 09/10/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 678821211
Principal investigator 1 Clovis Oncology, Inc. $2,191.25 09/06/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689454997
Principal investigator 1 Merck Sharp & Dohme Corporation $257.97 08/29/2019 Non-covered Recipient Entity
TAUSSIG CANCER INSTITUTE CLEVELAND
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 691474391
Principal investigator 1 PFIZER INC. $13,304.50 08/15/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE 3 MULTICENTER RANDOMIZED OPENLABEL STUDY OF AVELUMAB MSB0010718C ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUMRESISTANTREFRACTORY OVARIAN CANCER No dispute reported 06/30/2026 671661999
Principal investigator 1 Genentech, Inc. $11,588.00 08/13/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125795
Principal investigator 1 TESARO, Inc. $34,568.10 08/12/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689412557
Principal investigator 1 Seattle Genetics, Inc. $2,800.63 07/23/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 678821209
Principal investigator 1 Clovis Oncology, Inc. $2,357.50 07/22/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689454995
Principal investigator 1 Genentech, Inc. $9,197.00 06/24/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125785
Principal investigator 1 TESARO, Inc. $17,284.05 06/20/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689411783
Principal investigator 1 Merck Sharp & Dohme Corporation $41,560.00 06/19/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 691297463
Principal investigator 1 Seattle Genetics, Inc. $20,780.00 06/19/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 678821215
Principal investigator 1 Clovis Oncology, Inc. $11,325.00 06/17/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689454993
Principal investigator 1 Merck Sharp & Dohme Corporation $2,600.00 06/05/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 691297457
Principal investigator 1 Seattle Genetics, Inc. $1,300.00 06/05/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer No dispute reported 06/30/2026 678821213
Principal investigator 1 TESARO, Inc. $17,284.05 05/23/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689411549
Principal investigator 1 Genentech, Inc. $18,823.00 05/13/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125775
Principal investigator 1 Genentech, Inc. $9,507.00 05/13/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125779
Principal investigator 1 Merck Sharp & Dohme Corporation $2,167.02 05/09/2019 Non-covered Recipient Entity
TAUSSIG CANCER INSTITUTE CLEVELAND
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 691474384
Principal investigator 1 Clovis Oncology, Inc. $2,053.75 05/01/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689454991
Principal investigator 1 Merck Sharp & Dohme Corporation $619.15 04/02/2019 Non-covered Recipient Entity
TAUSSIG CANCER INSTITUTE CLEVELAND
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 691465847
Principal investigator 1 Merck Sharp & Dohme Corporation $980.32 04/02/2019 Non-covered Recipient Entity
TAUSSIG CANCER INSTITUTE CLEVELAND
A Phase 2 Open-Label Trial of Tisotumab Vedotin HuMax TF ADC alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer No dispute reported 06/30/2026 691467765
Principal investigator 1 Clovis Oncology, Inc. $4,511.25 03/21/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689454989
Principal investigator 1 Clovis Oncology, Inc. $2,600.00 02/25/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689454985
Principal investigator 1 Clovis Oncology, Inc. $27,650.00 02/25/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) No dispute reported 06/30/2026 689454987
Principal investigator 1 Genentech, Inc. $9,245.00 02/12/2019 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857125789
Principal investigator 1 TESARO, Inc. $34,568.10 01/31/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689409913
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,818.43 01/29/2019 Covered Recipient Teaching Hospital
Cleveland Clinic Hospital
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with a germline BRCA mutation and Stage III-IV Ovarian Cancer who are in Complete or Partial Response Following First Line Platinum Based Chemotherapy No dispute reported 06/30/2026 685003429
Principal investigator 1 TESARO, Inc. $17,284.05 01/23/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689409813
Principal investigator 1 TESARO, Inc. $34,568.10 01/02/2019 Non-covered Recipient Entity
CLEVELAND CLINIC MAIN CAMPUS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY No dispute reported 06/30/2026 689409367